332 related articles for article (PubMed ID: 26881893)
1. Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors.
van Weely SF; Kneepkens EL; Nurmohamed MT; Dekker J; van der Horst-Bruinsma IE
Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1522-9. PubMed ID: 26881893
[TBL] [Abstract][Full Text] [Related]
2. Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.
Poddubnyy D; Fedorova A; Listing J; Haibel H; Baraliakos X; Braun J; Sieper J
J Rheumatol; 2016 Dec; 43(12):2142-2148. PubMed ID: 27803139
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
van der Heijde D; Breban M; Halter D; DiVittorio G; Bratt J; Cantini F; Kary S; Pangan AL; Kupper H; Rathmann SS; Sieper J; Mease PJ
Rheumatology (Oxford); 2015 Jul; 54(7):1210-9. PubMed ID: 25541333
[TBL] [Abstract][Full Text] [Related]
5. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
[TBL] [Abstract][Full Text] [Related]
6. Performance of ultrasound to monitor Achilles enthesitis in patients with ankylosing spondylitis during TNF-a antagonist therapy.
Wang CH; Feng Y; Ren Z; Yang X; Jia JF; Rong MY; Li XY; Wu ZB
Clin Rheumatol; 2015 Jun; 34(6):1073-8. PubMed ID: 25896532
[TBL] [Abstract][Full Text] [Related]
7. Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.
Hebeisen M; Neuenschwander R; Scherer A; Exer P; Weber U; Tamborrini G; Micheroli R; Wildi LM; Zufferey P; Nissen MJ; Villiger PM; Bernhard J; Finckh A; van der Horst-Bruinsma IE; Sieper J; Landewé R; van der Heijde D; Ciurea A;
J Rheumatol; 2018 Apr; 45(4):506-512. PubMed ID: 29449504
[TBL] [Abstract][Full Text] [Related]
8. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
Glintborg B; Østergaard M; Krogh NS; Tarp U; Manilo N; Loft AG; Hansen A; Schlemmer A; Fana V; Lindegaard HM; Nordin H; Rasmussen C; Ejstrup L; Jensen DV; Petersen PM; Hetland ML
Ann Rheum Dis; 2013 Jul; 72(7):1149-55. PubMed ID: 22941767
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.
Wang R; Dasgupta A; Ward MM
J Rheumatol; 2018 Apr; 45(4):481-490. PubMed ID: 29335342
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Subcutaneous Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Real-World Prospective Observational Cohort Study in China.
Ji X; Wang Y; Hu Z; Ma Y; Man S; Li K; Wang Y; Zhu J; Zhang J; Huang F
Front Pharmacol; 2019; 10():1476. PubMed ID: 31920662
[No Abstract] [Full Text] [Related]
11. Ankylosing Spondylitis Response to TNF Inhibition Is Gender Specific: A 6-Year Cohort Study.
Murray C; Fearon C; Dockery M; Moran D; Heffernan E; Fitzgerald O; Veale DJ; Harty L
Ir Med J; 2018 Oct; 111(9):820. PubMed ID: 30556668
[TBL] [Abstract][Full Text] [Related]
12. Objective evaluation of physical functioning after tumor necrosis factor inhibitory therapy in patients with ankylosing spondylitis: a selection of 3 feasible performance-based tests.
van Weely SF; Dekker J; Steultjens MP; van Denderen JC; Nurmohamed MT; Dijkmans BA; van der Horst-Bruinsma IE
J Rheumatol; 2015 Apr; 42(4):623-9. PubMed ID: 25593234
[TBL] [Abstract][Full Text] [Related]
13. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
14. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy.
Jauregui E; Conner-Spady B; Russell AS; Maksymowych WP
J Rheumatol; 2004 Dec; 31(12):2422-8. PubMed ID: 15570645
[TBL] [Abstract][Full Text] [Related]
15. Effect of tumor necrosis factor α inhibitors on spinal radiographic progression in patients with ankylosing spondylitis.
Jeong H; Eun YH; Kim IY; Park EJ; Kim H; Lee J; Jeon CH; Koh EM; Cha HS
Int J Rheum Dis; 2018 May; 21(5):1098-1105. PubMed ID: 29611287
[TBL] [Abstract][Full Text] [Related]
16. Fat Mass Lowers the Response to Tumor Necrosis Factor-α Blockers in Patients with Ankylosing Spondylitis.
Ibáñez Vodnizza SE; Nurmohamed MT; Visman IM; van Denderen JC; Lems WF; Jaime F; van der Horst-Bruinsma IE
J Rheumatol; 2017 Sep; 44(9):1355-1361. PubMed ID: 28711878
[TBL] [Abstract][Full Text] [Related]
17. Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort.
Protopopov M; Sieper J; Haibel H; Listing J; Rudwaleit M; Poddubnyy D
Arthritis Res Ther; 2017 Oct; 19(1):240. PubMed ID: 29065931
[TBL] [Abstract][Full Text] [Related]
18. [Relapse of ankylosing spondylitis and its predictors after withdrawal of tumor necrosis factor-α inhibitors: a 52-week follow-up study].
Tang C; Chen F; Zheng S; Wu L; Chen S; Zhu J; Li J
Nan Fang Yi Ke Da Xue Xue Bao; 2021 May; 41(5):633-639. PubMed ID: 34134948
[TBL] [Abstract][Full Text] [Related]
19. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
Park JW; Kim HA; Shin K; Park YB; Kim TH; Song YW; Lee EY
Arthritis Res Ther; 2019 Jul; 21(1):163. PubMed ID: 31272498
[TBL] [Abstract][Full Text] [Related]
20. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
